Home

M3Nephron

Changing Haemodialysis

M3Nephron develops mixed matrix membrane dialyzers applied in haemodialysis treatment which combine absorption and filtration for
  • Improved removal of protein bound uremic toxin removal from blood with low usage of dialysate
  • Dialysate regeneration and reuse supporting reduction of dialysate volumes

M3Nephron mixed matrix membranes facilitates implementation and simplification of home dialysis therapy and contribute to development of portable and wearable dialysis devices.

M3Nephron aims to improve clinical outcomes and quality of life for patients on dialysis and contribute to green dialysis therapy.

Company Focus

Improving dialysis and Quality of Life
M3Nephron is dedicated to transforming haemodialysis care for over 4 million chronic kidney disease patients worldwide. Addressing the limitations of current in-hospital dialysis -such as moderate clinical outcomes, high costs, environmental impact, and poor patient quality of life- M3Nephron has developed advanced mixed matrix membranes.

These innovative membranes enhance toxin removal from blood, regenerate dialysate using lower-quality water, and support portable and wearable dialysis devices. By enabling efficient, flexible, and home-based treatments without the need for complex water purification, M3Nephron’s technology aims to improve patient outcomes, reduce healthcare costs, and minimize environmental impact, setting a new standard in dialysis therapy.

Our Technology

Improved dialysis, reduced dialysate, lower carbon footprint

M3Nephron mixed matrixed membrane dialyzers provides improved toxin removal and efficient dialysate regeneration in today’s dialysis and in near future portable and wearable devices

Mixed matrixed membranes offers:

  • Better clearance of protein bound toxins in blood leading to improvement of clinical outcomes
  • Reduced dialysate volumes 
  • Support of lower quality water in home dialysis or in near-by –home dialysis hubs
  • Reduced  carbon footprint by lowering energy and water consumption
  • Suitable for wearable and portable devices

Company Status

M3Nephron B.V. is founded in 2025 in cooperation with Twente University, the Netherlands to further develop the innovative mixed matrix membranes and prepare for commercialization.

The company has a strong patent portfolio for the development and commercialization of mixed matrix membranes in current haemodialysis treatments and also for future portable and wearable devices. The feasibility studies of the Mixed Matrix Membranes first product version are nearly finished and M3Nephron aims to market launch in 2029. Meanwhile we are preparing for clinical validations, CE-marking and FDA approval with our development partners.

Our Team

News from M3Nephron